SCHEMBL6206973

SCHEMBL6206973

Cn1c(=O)cc(O)c2cc(OC(F)F)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
HSD17B10 Q99714 2/20 0.43
THRB P10828 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MCHR1 Q99705 1/20 0.43
BRD4 O60885 1/20 0.40
BRPF1 P55201 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 3/20 0.38
POLB P06746 2/20 0.38
HTR3E A5X5Y0 1/20 0.37
HTR3B O95264 1/20 0.37
HTR3A P46098 1/20 0.37
HTR3D Q70Z44 1/20 0.37
HTR3C Q8WXA8 1/20 0.37
HIF1A Q16665 2/20 0.37
LMNA P02545 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9287885 0.83 KDM4E (0.43) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6208739 0.82 MAPT (0.56) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL30099642 0.75 KDM4E (0.50) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL13440436 0.75 KDM4E (0.50) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL28882660 0.74 BRD4 (0.40) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2266978 0.73 KDM4E (0.51) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL19231301 0.73 BRPF1 (0.47) ALDH1A1HPGDNPSR1MCHR1BRD4
SCHEMBL25269828 0.72 KDM4E (0.50) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL20680340 0.72 KDM4E (0.50) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL11836043 0.70 ALDH1A1 (0.48) MAPTKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921821-B2 Antagonists of melanin concentrating hormone receptor ABBOTT LABORATORIES (US) 2005-07-26 US disclosed
EP-1534703-A2 ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR ABBOTT LABORATORIES (US) 2005-06-01 EP disclosed
US-20040106645-A1 Antagonists of melanin concentrating hormone receptor MILLENNIUM PHARMACEUTICALS, INC. 2004-06-03 US disclosed
WO-2003106452-A2 ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106645-A1 Antagonists of melanin concentrating hormone receptor MCHR1, MCHR2, MC1R MAPT 4185/4885KDM4E 1548/4885ALDH1A1 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.